Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04439825 · ClinicalTrials.gov registry record · Phase 1
Impact of Botox Treatment Into the Upper One Third of the Face an Area on Mood and Self -Appearance Satisfaction
A Phase 1 study of Mood, sponsored by DeNova Research.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT04439825: Completed Phase 1 study of Mood, sponsored by DeNova Research.
NCT04439825 is a Phase 1 study of Mood that has completed, run by DeNova Research. The registered enrollment target is 45 participants, below the 3,658-participant average among 29 other Mood trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04439825, a Phase 1 study of Mood, has completed, sponsored by DeNova Research.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
Botox treatment into the upper one third of the face (glabella, forehead lines and/or lateral canthal lines) to analyze mood and self -appearance satisfaction in a Post Covid period on non-naïve Botox patients
Primary Outcome
Treatment with Botox into the glabellar furrows increase the self- satisfaction with appearance once optimal correction is achieved beyond baseline in non -naïve users as compared to a control group and to themselves.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Botulinum Neurotoxin
Study Locations (1)
Illinois
- DeNova Research - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2020-07-20 |
| Est. Completion | 2020-12-01 |
| Phase | Phase 1 |
What the finished NCT04439825 record still lists
NCT04439825 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 3,658-participant average among 29 other Mood trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Mood appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04439825 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT04439825 about?
NCT04439825 is a clinical study titled "Impact of Botox Treatment Into the Upper One Third of the Face an Area on Mood and Self -Appearance Satisfaction". Botox treatment into the upper one third of the face (glabella, forehead lines and/or lateral canthal lines) to analyze mood and self -appearance satisfaction in a Post Covid period on non-naïve Botox patients
What is the current status of trial NCT04439825?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2020-07-20. Estimated completion is 2020-12-01.
What conditions does trial NCT04439825 study?
This clinical trial studies the following conditions: Mood.
What interventions are being tested in trial NCT04439825?
The interventions under investigation include: Placebo (DRUG), Botulinum Neurotoxin (DRUG).
Who is sponsoring clinical trial NCT04439825?
This trial is sponsored by DeNova Research, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04439825 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mood
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04439825's enrollment target sits among peer trials
45 16th of 29 higher than 14 of 29 other Mood trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mood trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Student Exercise and Sleep Timing Study - Part 2
RECRUITING · NA
-
Research Framework Exploring Sleep Health
RECRUITING
-
Efficacy and Safety of Shatavari for Treatment of Menopausal Symptoms in Women: A Randomized, Double-blind, Three-arm, Parallel, Placebo-controlled Study
RECRUITING · NA
-
Developing Resilience and Anxiety Management Through the Arts
RECRUITING · NA
-
Technology Exposure and Child Health: Wellness Impact and Social Effects: an Observational Product Registry Study
RECRUITING
-
Contraceptive Hormone and Reward Measurement (CHARM Study)
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI